中国现代医生Issue(30)：94-97,4.
北京、上海、广州、天津、杭州、成都六城市α-葡萄糖苷酶抑制剂使用情况比较
Analysis and comparison of the utilization of α-Glucosidase inhibitors in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou, and Chengdu
摘要
Abstract
Objective To analyze and compare utilization of α-glucosidase inhibitors in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou, and Chengdu. Methods It was summarized in the article name, specification, number of prescrip-tion, dispensary quantity and amount of Acarbose, Voglibose, and Miglitol. Results Respectively in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou and Chengdu, DDDs of Acarbose were 1 561 598.00, 444 800.17, 368 790.33, 624 876.00, 183 533.67, and 111 732.17; DDC of Acarbose were 14.56, 14.18, 13.88, 14.09, 13.58, and 13.49; DDDs of Voglibose were 40 393.83, 80 826.67, 70 604.17, 107 670.67, 28 642.50, and 270.00; DDC of Voglibose were 13.44, 12.80, 13.07, 13.28, 12.41, and 12.12. While in Shanghai and Chengdu DDDs of Miglitol were 36.00 and 29 170.00; DDC of Miglitol were 18.54 and 14.10. Conclusion Low DDC reveals superior economics properties on all three kinds of drugs. Acarbose and Voglibose are more frequently used in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou; while Acarbose and Miglitol more frequently in Chengdu, which suggests a large market ofα-glucosidase inhibitors in metropolis.关键词
琢-葡萄糖苷酶抑制剂/糖尿病/处方/城市/比较Key words
α-Glucosidase inhibitors/Diabetes/Prescription/City/Comparison分类
医药卫生引用本文复制引用
王茜,王莉文..北京、上海、广州、天津、杭州、成都六城市α-葡萄糖苷酶抑制剂使用情况比较[J].中国现代医生,2014,(30):94-97,4.基金项目
浙江省重点科技创新团队项目 （）
